September 7, 2018
PhaseBio Secures $34 Million in Series D Financing
“PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for orphan diseases, with an initial focus on cardiopulmonary disorders, today announced the completion of a $34 million Series D financing, including the conversion of existing convertible promissory notes.”
Proceeds from this financing will advance clinical development of PB2452, which is a potential first-in-class reversal agent for patients on ticagrelor, and PB1046, a novel treatment for PAH. PhaseBio, a clinical-stage biopharmaceutical company launched in 2006 from Duke innovators Drs. Ashutosh Chilkoti & Lori Setton are committed to developing new and improved biotherapeutics for the treatment of serious rare diseases, with an initial focus on cardiopulmonary indications.
[Originally posted by PhaseBio — September 5, 2018]